ImexpharmSTC:IMP 97 Receivables Turnover is 1.52 as of Mar. 2026. GuruFocus rates STC:IMP with a GF Score™ of 97/100 and a GF Value™ of ₫52,260.37 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 946 Drug Manufacturers companies, Imexpharm ranks better than 63.53% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Imexpharm's Revenue for the
three
months ended in Mar. 2026 was ₫546,206 Mil. Imexpharm's average Accounts Receivable for the
three
months ended in Mar. 2026 was ₫359,645 Mil.
Hence, Imexpharm's Receivables Turnover for the
three
months ended in Mar. 2026 was 1.52.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Imexpharm Receivables Turnover Related Terms
Imexpharm Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Imexpharm's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STC:IMP vs ZTS, UTHR: Receivables Turnover Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Imexpharm's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Imexpharm Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Imexpharm's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Imexpharm's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Imexpharm (STC:IMP) has a Receivables Turnover of 1.52 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Imexpharm and its competitors. According to the industry distribution chart, Imexpharm ranks #345 out of 946 companies in the Drug Manufacturers industry, placing it in the top 36.5%.
Is Imexpharm's Receivables Turnover too high?
Imexpharm's current Receivables Turnover is 1.52. The Drug Manufacturers industry median Receivables Turnover is 5.07. Imexpharm's value of 1.52 is 70% below this industry median. Based on the distribution chart, Imexpharm ranks #345 out of 946 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Imexpharm has a GF Score™ of 97/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Imexpharm's Receivables Turnover compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Imexpharm ranks #345 out of 946 companies for Receivables Turnover. This puts Imexpharm in the upper half of its industry. The industry median Receivables Turnover is 5.07. Imexpharm's value of 1.52 is 70% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.07, based on 946 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Imexpharm's current Receivables Turnover of 1.52 is 70% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Imexpharm and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Imexpharm's current Receivables Turnover is 1.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Imexpharm stock overvalued right now?
Based on GuruFocus' analysis, Imexpharm (STC:IMP) is currently considered Modestly Undervalued. The stock's GF Value™ is ₫52,260.37, compared to a current price of ₫42,950.00 — trading 17.8% below its estimated fair value. The current Receivables Turnover is 1.52 and 70% below the Drug Manufacturers industry median of 5.07. Imexpharm's overall GF Score™ is 97/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Imexpharm (STC:IMP), the current Receivables Turnover is 1.52 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Imexpharm (STC:IMP) Overvalued in 2026?
Based on GuruFocus' analysis, Imexpharm stock appears to be undervalued.
The current stock price of ₫42,950.00 is trading 17.8% below its estimated GF Value™ of ₫52,260.37.
GuruFocus considers Imexpharm to be Modestly Undervalued.
Key valuation signals for STC:IMP:
Receivables Turnover: 1.52
GF Value™: ₫52,260.37 vs. price of ₫42,950.00 (17.8% below fair value)
Industry Position: 70% below the Drug Manufacturers median (#345 of 946)
No single metric tells the full story. See the STC:IMP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Imexpharm Corp is engaged in the manufacture, import, export, and trade of pharmaceuticals and medicinal chemical products. The company's products include oral and injective antibiotic, digestion, central nervous system, cardiovascular, diabetes, musculoskeletal system, respiratory system, analgesic-anti-inflammatory, anti-allergy, ophthalmology, external drugs, and anti-parasitic, as well as vitamins and minerals.
97GF Score
Get the complete analysis for STC:IMP
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STC:IMP has been successfully added to your 
